18 results
6-K
EX-1.1
ACIU
AC Immune SA
19 Dec 23
Current report (foreign)
8:53am
of Rule 433 under the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing
6-K
EX-99.2
ACIU
AC Immune SA
28 Apr 22
Current report (foreign)
7:37am
retention in brain areas affected by MSA disease processes. Together with preclinical data also presented at AD/PDTM 2022, these analyses demonstrate ACI
6-K
EX-99.3
ACIU
AC Immune SA
28 Apr 22
Current report (foreign)
7:37am
enhanced contrast and a-syn target specificity in patients with multiple system atrophy (MSA), as well as increased tracer retention in brain areas
6-K
EX-99.1
3oig n4azxaoi330b
16 Mar 22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
7:51am
6-K
EX-10.1
fm2ti3 c08
4 Aug 21
Current report (foreign)
7:21am
6-K
EX-1.1
x9nn 97279yyeudyrbot
5 May 21
Current report (foreign)
4:53pm
6-K
EX-99.2
eajwue5 4w
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
9:06am
6-K
EX-1.1
brzlmy xze5
8 Sep 20
Current report (foreign)
5:17pm
20-F/A
EX-4.14
8ez5sngyt5bfczp0s
19 Apr 19
Annual report (foreign) (amended)
5:07pm
6-K
EX-1.1
p1z7lz 549wl
23 Jul 18
Current report (foreign)
4:06pm
20-F
boq7g49
17 Mar 17
Annual report (foreign)
12:00am
- Prev
- 1
- Next